priors.science/reviews/her2-targeted-therapy

HER2 Targeted Therapy

The current evidence on 15 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

15claims tracked
139primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
11 Established · 3 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Trastuzumab reduces recurrence in early HER2-positive breast cancerEarly Breast CancerEstablished94%11
Pertuzumab plus trastuzumab: first-line standardMetastatic BreastEstablished94%14
T-DXd active in HER2-mutant lung cancerOther TumoursEstablished94%11
T-DXd superior to T-DM1 in metastatic HER2-positive breast cancerMetastatic BreastEstablished93%9
T-DM1 improves outcomes in residual diseaseEarly Breast CancerEstablished92%11
Pertuzumab improves pathological complete response in the neoadjuvant settingEarly Breast CancerEstablished91%11
T-DXd active in HER2-low breast cancerHER2 LowEstablished91%12
Cardiotoxicity: HER2-targeted therapy class adverse effectOther TumoursEstablished91%9
Trastuzumab improves survival in HER2-positive gastric cancerOther TumoursEstablished89%10
Tucatinib triplet improves survival in HER2-positive breast cancerMetastatic BreastEstablished87%9
Tucatinib reduces central nervous system progression in HER2-positive breast cancerCNS ResistanceEstablished86%9
T-DXd has central nervous system activity in HER2-positive breast cancerCNS ResistanceLikely84%9
T-DXd active in HER2-amplified colorectal cancerOther TumoursLikely82%9
PI3K pathway drives trastuzumab resistanceCNS ResistanceLong-standingLikely78%8
HER2-low is a distinct therapeutic categoryHER2 LowUncertain62%10
Track HER2 Targeted Therapy.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.